Abstract
Background and Aims : Bempedoic acid, an inhibitor of ATP citrate lyase, reduces low-density lipoprotein cholesterol (LDL-C) and since 2020 has become an additional treatment option to reach the LDL-C treatment goal. The aim of this analysis is to provide new data of side effects and efficacy of bempedoic acid in a “real-world” cohort.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
